AbbVie (ABBV) Financial Analysis & Valuation | Quarter Chart
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor f... more
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The compa... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $469.54B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert A. Michael |
| IPO Date | 2013-01-02 | CAGR | 9.55% |
| Employees | 57,000 | Website | www.abbvie.com |
| Div. Yield | 0.79% | Payout Ratio | 187% |
| Buy Back Yield | 0.09% | Total Yield | 0.88% |
ABBV chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $471.95B | P/E | 26.08 | Forward P/E | 16.16 | PEG | 0.25 |
| P/S | 23.74 | P/B | -229.61 | P/CF | 72 | P/FCF | 73.13 |
| Sales | $64.39B | Sales 1Y | 10.39% | Sales 3Y | 14.93% | Sales 5Y | 19.83% |
| EPS | $10.19 | EPS 1Y | 68.06% | EPS 3Y | -27.27% | EPS 5Y | -4.37% |
| Sales QoQ | 13.25% | EPS QoQ | 423.08% | Sales QoQ Avg | 2.79% | EPS QoQ Avg | 301.81% |
| Gross Margin | 74.1% | Operating Margin | 29.77% | Profit Margin | 9.82% | ROCE | 20.32% |
| ROA | 5% | ROE | -198% | Altman Z Score | 2.5 | Piotroski Score | 6 |
| Current Ratio | 0.8 | Quick Ratio | 0.68 | Cash Ratio | 0.22 | Op. CF Ratio | 0.09 |
| Debt/Equity | -10.95 | Debt/Assets | 0.53 | Lt Debt/Equity | -9.7 | Lt Debt/Cap. | 1.12 |
| Intrst Cov. | 6.73 | Inventory Turnover | 3.3 | Asset Turnover | 0.47 | Receivables Turnover | 5.16 |
| Enterprise Value | $471.95B | P/E Ratio | 26.08 |
| Forward P/E | 16.16 | PEG Ratio | 0.25 |
| P/S Ratio | 23.74 | P/B Ratio | -229.61 |
| P/CF Ratio | 72 | P/FCF Ratio | 73.13 |
| EPS | $10.19 | EPS Growth 1Y | 68.06% |
| EPS Growth 3Y | -27.27% | EPS Growth 5Y | -4.37% |
| Revenue Growth 1Y | 10.39% | Gross Margin | 74.1% |
| Operating Margin | 29.77% | Profit Margin | 9.82% |
| ROE | -198% | ROA | 5% |
| ROCE | 20.32% | Current Ratio | 0.8 |
| Quick Ratio | 0.68 | Cash Ratio | 0.22 |
| Debt/Equity | -10.95 | Interest Coverage | 6.73 |
| Altman Z Score | 2.5 | Piotroski Score | 6 |
AbbVie (ABBV) valuation & financials
AbbVie (ABBV) has a market capitalization of $469.54B and trades at a price-to-earnings ratio of 26.1. It operates in the Healthcare sector (Drug Manufacturers - General).
AbbVie's revenue grew +10.4% over the last year.
AbbVie's next earnings report is scheduled for October 30, 2026 before market open (provider scheduled date); analysts estimate EPS of $3.86. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW) · Novartis (NVS)